Anthony T Vesco1, Andrea S Young2, L Eugene Arnold3, Mary A Fristad3. 1. Department of Psychiatry, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA. 2. Division of Child & Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD, USA. 3. Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA.
Abstract
BACKGROUND: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. METHODS:Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. RESULTS: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p = .001, d = .70), BRI (p = .004, d = .49), and MI (p = .04, d = .41). Ω3 alone (d = .49) and combined with PEP (d = .67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. CONCLUSIONS: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.
RCT Entities:
BACKGROUND: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder. METHODS: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753. RESULTS:Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p = .001, d = .70), BRI (p = .004, d = .49), and MI (p = .04, d = .41). Ω3 alone (d = .49) and combined with PEP (d = .67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect. CONCLUSIONS:Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.
Authors: Vilma Gabbay; Rachel G Klein; Yisrael Katz; Sandra Mendoza; Leah E Guttman; Carmen M Alonso; James S Babb; Glenn S Hirsch; Leonard Liebes Journal: J Child Psychol Psychiatry Date: 2010-04-12 Impact factor: 8.982
Authors: Jutta M Wolf; Nicolas Rohleder; Angelika Bierhaus; Peter P Nawroth; Clemens Kirschbaum Journal: Brain Behav Immun Date: 2008-09-26 Impact factor: 7.217
Authors: Robert K McNamara; Jeffrey R Strawn; Max J Tallman; Jeffrey A Welge; L Rodrigo Patino; Thomas J Blom; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2020-03-11 Impact factor: 2.576
Authors: Jochen Seitz; Beate Herpertz-Dahlmann; Lara Keller; Astrid Dempfle; Brigitte Dahmen; Samira Schreiber; Roger A H Adan; Nadia Andrea Andreani; Unna N Danner; Albrecht Eisert; Sergueï Fetissov; Florian Ph S Fischmeister; Andreas Karwautz; Kerstin Konrad; Karlijn L Kooij; Stefanie Trinh; Benny van der Vijgh; Annemarie A van Elburg; Michael Zeiler; John Baines Journal: Trials Date: 2022-07-05 Impact factor: 2.728
Authors: Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz Journal: J Affect Disord Date: 2020-03-06 Impact factor: 4.839